Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance) Abou-Alfa, Ghassan K. , Niedzwieski, Donna , Knox, Jennifer J. ... - ASCO GI - J. Clin. Oncol. - 2016 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80802
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - - JAMA Oncol - 2019 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-80802
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8) Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80802
A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study. Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0426
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426 Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2010 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0426
A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer. Adjei, A. A. , Molina, J. R. , Hillman, S. L. , Luyun, R. F. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0326
Correlation between polymorphisms in the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer (NSCLC): An NCCTG N0026 based study. Abstract 198. Adjei, A. , Salavaggione, O. , Mandrekar, S. , Dy, G. ... - NCI TSM - - 2009 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - NCCTG-N0026
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. Adjei, Araba A , Salavaggione, Oreste E , Mandrekar, Sumithra J ... - - J Thorac Oncol - 2010 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - N0026
Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance) Advani, Anjali S. , Sanford, Ben , Luger, Selina , Devidas, Meenakshi ... - ASH - Blood - 2013 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - C10403
Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial Advani, Pooja P. , Ballman, Karla V. , Dockter, Travis J. ... - - J. Clin. Oncol - 2016 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831
Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial. Advani, Pooja Prem , Ballman, Karla V. , Dockter, Travis J. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Advani, Ranjana H , Chen, Haiyan , Habermann, Thomas M ... - - Br. J. Haematol. - 2010 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Older Adult - C9793
The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy with Docetaxel in Patients with Metastatic Castrate Resistant Prostate Cancer: Results from a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance) Aggarwal, Rahul , Halabi, Susan , Kelly, William Kevin ... - - Cancer - 2013 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401
Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM) CALGB 100104 (Alliance) Ailawadhi, Sikander , McCarthy, Philip L. , Holstein, Sarah A. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Transplant - CALGB-100104 , E4A03 , MM-002 , MM-009
Management of Recurrent Prostate Cancer after Radiotherapy: Long-term results from CALGB 9687, a Contemporary Prospective Multi-institutional Salvage Prostatectomy Series Al-Daghmin, A , Sokoloff, MH , Halabi, S , Sanford, BL , Eastham, JA ... - AUA - J Urology - 2014 Abstract - Primary Endpoint - Long-Term-Followup Analysis - GU - CALGB-9687
Comparative Age-Based Prospective Multi-Institutional Observations from 12,367 Patients Enrolled to American College of Surgeons Oncology Group (ACOSOG Z901101) Trials (Alliance) Al-Refaie, Waddah B. , Decker, Paul A. , Ballman, Karla V. ... - - Ann. Surg. Oncol. - 2019 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Older Adult - Z901101
Attributes and Outcomes of Older Adults in Surgical Oncology Trials: Results from ACOSOG Z901101 (Alliance) Al-Refaie, Waddah B. , Decker, Paul A. , Pisters, Peter W.T. ... - SSO - Ann. Surg. Oncol. - 2015 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Older Adult - Z901101
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia Alachkar, Houda , Fulton, Noreen , Sanford, Ben , Malnassy, Greg ... - - Pharmacogenomics J. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10102
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome Alachkar, Houda , Santhanam, Ramasamy , Maharry, Kati ... - - J. Clin. Invest - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-9621
Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver Alberts, S. R. , Donohue, J. H. , Mahoney, M. R. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N014A
NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary Endpoint - Preliminary Analysis - GI - NCCTG-N044J
Adjuvant mFOLFOX6 +/- Cetuxiumab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147. Alberts, S. R. , Sargent, D. J. , Smyrk, T. C. , Shields, A. F. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0147
Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. Alberts, S. R. , Thibodeau, S. N. , Sargent, D. J. , Mahoney, M. R. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - NCCTG-N0147
Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver. Alberts, S. , Mahoney, M. R. , Donohue, J. H. , Roh, M. S. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N9945
Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849 Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Preliminary Analysis - GI - N0849
Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Fitch, Tom R. , Kim, George P. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N044J
Gemcitabine and Doxetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Reid, Joel M. , Morlan, Bruce W. , Farr, Gist H. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N0041
Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66 Alberts, Steven R. , Roh, Mark S. , Mahoney, Michelle R. ... - - J Clin Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - GI - N9945
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer Alberts, Steven R. , Sargent, Daniel J. , Nair, Suresh ... - - JAMA - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N0147
Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. Alberts, Steven R , Sande, Jonathan R , Foster, Nathan R ... - - J Gastrointest Cancer - 2007 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-N9943
Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. Alberts, Steven R , Suman, Vera J , Pitot, Henry C ... - - J Gastrointest Cancer - 2007 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-964251
Computed tomography densitometry and morphology of radiofrequency ablated Stage IA non-small cell lung cancer: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial Alexander, Erica S. , Xiong, Lillian , Baird, Grayson L. ... - - J Vasc Interv Radiol - 2020 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4033
Exercise and Dietary Change after Diagnosis and Cancer-related Symptoms in Long-term Survivors of Breast Cancer: CALGB 79804 Alfano, Catherine M. , Day, Jeannette M. , Katz, Mira L. ... - - Psychooncology - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Health Outcome - CALGB-70804
ACOSOG Z0030 Study Group: Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective ACOSOG Z0030 trial Allen, M. S. , Darling, G. E. , Decker, P. A. , Putnam, J. B. Jr ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
Perioperative mortality and Morbidity after Lobar versus Sublobar Resection for early stage lung cancer: A post-hoc analysis of an international randomized phase III trial (CALGB/Alliance 140503) Altorki, Nasser K. , Wang, Xiaofei , Wigle, Dennis , Gu, Lin ... - AATS - - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-140503
Perioperative mortality and Morbidity after Lobar versus Sublobar Resection for early stage lung cancer: A post-hoc analysis of an international randomized phase III trial (CALGB/Alliance 140503) Altorki, Nasser K. , Wang, Xiaofei , Wigle, Dennis , Gu, Lin ... - - Lancet Respir Med - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0010
Par-4 Down-regulation Promotes Breast Cancer Recurrence by Preventing Multinucleation following Targeted Therapy Alvarez, James V. , Pan, Tien-chi , Ruth, Jason , Feng, Yi ... - - Cancer Cell - 2013 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods An, Ming-Wen , Han, Yu , Meyers, Jeffrey P. , Bogaerts, Jan ... - - J. Clin. Oncol - 2015 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N9741
Exploring the statistical and clinical impact of two interim analyses on the phase II design with option for direct assignment An, Ming-Wen , Mandrekar, Sumithra J. , Edelman, Martin J. ... - - Contemp Clin Trials - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-30203
Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR). Anderson, S. K. , Lafky, J. M. , Carrero, X. W. , Kimlinger, T. K. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N0776
Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902. Anderson, S. Keith , Miller, C. Ryan , Sarkaria, Jann N. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary Endpoint - Primary Analysis - Neuro-Onc - N0874 , ABTC-0902
Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) -- Findings from the ACCENT dataset. Andre, T. , Shi, Q. , Yothers, G. , Bot, B. , Haller, D. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
Phase II clinical trial of denileukin diftitox in combination with rituximab in previously untreated follicular B-cell non-Hodgkins lymphoma Ansell, S. M. , Tang, H. , Nowakowski, G. S. , Nikcevich, D. A. ... - ASH - 53rd ASH Annual Meeting and Exposition - 2010 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - NCCTG-N0682
Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma Ansell, Stephen M. , Inwards, David J. , Rowland, Kendrith M. ... - - Cancer - 2008 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - N0186
Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma Ansell, Stephen M. , Novak, Anne J. , Ziesmer, Steven ... - - Am J Hematol - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Lymphoma - NCCTG-98-78-51
Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study Ansell, Stephen M. , Tang, Hui , Kurtin, Paul J. ... - - Lancet Oncol - 2011 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - N038H
Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma Ansell, Stephen M. , Tang, Hui , Kurtin, Paul J. ... - - Leukemia - 2012 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - NCCTG-N0682
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). Anurag, Meenakshi , Zhu, Mayanne , Huang, Chen , Vasaikar, Suhas ... - - J. Natl. Cancer Inst. - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1031
Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data Apoe, Ogheneruona , Jung, Sin-Ho , Liu, Heshan , Seisler, Drew K ... - - Am J Hematol Oncol - 2016 Manuscript - Primary Endpoint - Preliminary Analysis - Prevention - CALGB-70806
Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy Apolo, Andrea B. , Ostrovnaya, Irina , Halabi, Susan ... - - J. Natl. Cancer Inst - 2013 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90102
External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy. Apolo, Andrea Borghese , Philips, George , Ostrovnaya, Irina ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90102
Alliance A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (MIBC) (AMBASSADOR) vs Observation Apolo, Andrea , Rosenberg, Jonathan , Morris, Michael ... - ASCO GU - J Clin Oncol - 2019 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GU - A031501
Surgical practice patterns following NCCTG N0338 Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer. Apsey, H. , Roy, V. , Pockaj, B. , Northfelt, D. , Sticca, R. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - NCCTG-N0338
Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: Results of ACOSOG (American College Of Surgeons Oncology Group) Z1071 (Alliance) Substudy Armer, Jane M. , Ballman, Karla V. , McCall, Linda , Armer, Nathan C. ... - - Support Care Cancer - 2019 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection Armer, Jane M. , Ballman, Karla V. , McCall, Linda , Ostby, Pamela L. ... - - JAMA Surg - 2019 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Lymphedema results of Alliance Z1071 (American College of Surgeons Oncology Group [ACOSOG]): Self-reported symptoms and limb volume changes for breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - ILF - - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Symptoms and limb changes for breast cancer survivors treated with neoadjuvant chemotherapy: Lymphedema results of ACOSOG Z1071 (Alliance) Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - MASCC / ISOO - Supportive Cancer Care - 2017 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Effects of a lymphedema prevention intervention on range of motion among women receiving axillary node dissection for breast cancer treatment (Alliance) CALGB 70305 Armer, Jane M , Liu, Heshan , Oliveri, Jill , Seisler, Drew , tbd ... - ASCO CSS - J. Clin. Oncol. - 2018 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - CALGB-70305
Healthy Eating Index Scores are Associated with Inflammatory Markers in Breast Cancer Survivors Arnold, Kristen , Andridge, Rebecca , Logan, Amanda , Yee, Lisa ... - EB - FASEB J - 2015 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - NCT01478477
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Ashley, Amanda C , Sargent, Daniel J , Alberts, Steven R ... - - Cancer - 2007 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - NCCTG-9741
Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993). Atherton, P. , Burger, K. , Loprinzi, C. , Miller, R. , Jatoi, A. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - NCCTG-N0993
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993) Atherton, Pamela J. , Burger, Kelli N. , Loprinzi, Charles L. ... - - Support Care Cancer - 2012 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N0993
Assessment of Patient-Reported Measures of Bowel Function Before and After Pelvic Radiotherapy: An Ancillary Study of the North Central Cancer Treatment Group Study N00CA Atherton, Pamela J. , Halyard, Michele Y. , Sloan, Jeff A. ... - - Support Care Cancer - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Symptom Inter - N00CA
The Complementary Nature of Patient-Reported Outcomes (PROs) and Adverse Event Reporting in Cooperative Group Oncology Clinical Trials: A Pooled Analysis (NCCTG N0591) Atherton, Pamela J. , Watkins-Bruner, Deborah W. , Gotay, Carolyn ... - - J Pain Symptom Manage - 2015 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - N0591
Patient Reported Outcomes Questionnaire Compliance in Cancer Cooperative Group Trials (Alliance N0992) Atherton, Pamela J , Burger, Kelli N , Pederson, Levi D ... - - Clin Trials - 2016 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - N0992
Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials Atkinson, Thomas M. , Dueck, Amylou C. , Satele, Daniel V. ... - - JAMA Oncol - 2019 Manuscript - Secondary Endpoint - Meta-Analysis Analysis - Health Outcome - N0591
Measurement of Affective and Activity Pain Interference Using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903 Atkinson, Thomas M. , Halabi, Susan , Bennett, Antonia V. ... - - Pain Med - 2012 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - CALGB-70903
Comparison Between Clinician- and Patient-Reporting of Baseline (BL) and Post-BL Symptomatic Toxicities in Cancer Cooperative Group Clinical Trials (NCCTG N0591 [Alliance]) Atkinson, Thomas M. , Satele, Daniel V. , Sloan, Jeff A. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary Endpoint - Primary Analysis - Health Outcome - N0591
Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance) Attal, Michel , Palumbo, Antonio , Holstein, Sarah ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Myeloma - CALGB-100104
Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502 Attar, E. C. , Donohue, K. A. , Amrein, P. C. , Wadleigh, M. ... - - Blood - 2010 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-10502
A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. Attar, E. C. , Johnson, J. L. , Amrein, P. C. , Lozanski, G. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10502
Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study Attar, E. C. , Maharry, K. , Mrozek, K. , Radmacher, M. D. ... - ASH - Blood - 2009 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10502 , CALGB-20202 , CALGB-20502 , CALGB-8461
Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502 Attar, Eyal C. , Johnson, Jeffrey L. , Amrein, Philip C. ... - - J. Clin. Oncol. - 2013 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10502
Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance) Augert, Arnaud , Zhang, Qing , Bates, Breanna , Cui, Min ... - - J Thorac Oncol - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Sequencing - CALGB-151111
Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients >= 60 years (CALGB 9720) Baer, M. R. , George, S. L. , Sanford, B. L. , Bothun, S. M. ... - - Blood - 2007 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-8461 , CALGB-9720
Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies Baer, M. R. , George, S. L. , Sanford, B. L. , Stone, R. M. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - C8525 , CALGB-10201 , CALGB-8923 , CALGB-9720
Cancer and Leukemia Group B studies of recombinant Interleukin-2 maintenance therapy in acute myeloid leukemia Baer, M. R. , Kolitz, J. E. , George, S. L. , Caligiuri, M. A. ... - - Ann Hematol - 2008 Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Leukemia - CALGB-19808
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720 Baer, MR , George, SL , Sanford, BL , Mrózek, K , Kolitz, JE ... - - Leukemia - 2011 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-9720
Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J Clin Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-8461 , CALGB-9720
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8525 , CALGB-8923 , CALGB-9022 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance) Baggstrom, Maria Q. , Socinski, Mark A. , Wang, Xiaofei F. , Gu, Lin ... - - J Thorac Oncol - 2017 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30607 , CALGB-70701
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). Bajorin, Dean F , Halabi, Susan ... - - Clin Genitourin Cancer - 2009 Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-99903
A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101 Baldwin, R. Michael , Owzar, Kouros , Zembutsu, Hitoshi ... - - Clin. Cancer Res. - 2012 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40101
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme Ballman, Karla V. , Buckner, Jan C. , Brown, Paul D. ... - - Neuro-oncol - 2007 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N047D
Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators Bardia, A. , Loprinzi, C. , Grothey, A. , Nelson, G. , Alberts, S. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0148
Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators Bardia, Aditya , Loprinzi, Charles , Grothey, Axel , Nelson, Garth ... - - Semin Oncol - 2010 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0148
Age and the Risk of Paclitaxel‐Induced Neuropathy in Women with Early‐Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101 Barginear, Myra , Dueck, Amylou C. , Allred, Jacob B. ... - - Oncologist - 2019 Manuscript - Primary Endpoint - Primary Analysis - Older Adult - A151411 , CALGB-40101 , CALGB-70301
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Bartlett, N L , Niedzwiecki, D , Johnson, J L , Friedberg, J W ... - - Ann. Oncol. - 2007 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59804
A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: Preliminary results of CALGB 59804 Bartlett, N. , Niedzwiecki, D. , Johnson, J. , Friedberg, J. W. ... - - Proc Am Soc Clin Oncol - 2003 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59804
Phase II Study of 9-aminocamptothecin in Previously Treated Lymphomas: Results of Cancer and Leukemia Group B 9551 Bartlett, Nancy L. , Johnson, Jeffrey L. , Wagner-Johnston, Nina ... - - Cancer Chemother. Pharmacol. - 2009 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-9551
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 Bartlett, Nancy L. , Wilson, Wyndham H. , Jung, Sin-Ho , Hsi, Eric D. ... - - J. Clin. Oncol - 2019 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50303
The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5) Barton, D. L. , Atherton, P. J. , Bauer, B. A. , Moore, D. F. Jr ... - - J Support Oncol - 2011 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N01C5
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9 Barton, D. L. , Lavasseur, B. I. , Sloan, J. A. , Stawis, A. N. ... - - J. Clin. Oncol. - 2010 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N05C9
A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9 Barton, D. L. , Lavasseur, B. , Sloan, J. A. , Stella, P. J. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N05C9
Phase III evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N07C2 Barton, D. L. , Liu, H. , Dakhil, S. R. , Linquist, B. M. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N07C2
Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: A randomized, double-blind trial, N07C2 Barton, D. L. , Liu, H. , Dakhil, S. R. , Linquist, B. , Sloan, J. A. ... - - J. Natl. Cancer Inst. - 2013 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N07C2
Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7 Barton, D. L. , Moraska, A. R. , Sood, A. , Sloan, J. A. , Suh, J. J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N05C7
Can gabapentin improve control of delayed nausea and vomiting (N/V)? A phase III placebo controlled trial, N08C3 (Alliance) Barton, D. L. , Sloan, J. A. , Novotny, P. J. , Fuloria, J. ... - - Support Care Cancer - 2013 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N08C3
Does gabapentin prevent delayed chemotherapy-induced nausea and vomiting (N/V)? Results of a randomized placebo controlled trial, NCCTG N08C3 (Alliance) Barton, D. L. , Sloan, J. A. , Novotny, P. J. , Fuloria, J. ... - - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N08C3
A pilot, multi-dose, placebo-controlled evaluation of american ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N03CA Barton, D. L. , Soori, G. S. , Bauer, B. , Sloan, J. , Johnson, P. A. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N03CA
A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA Barton, D. L. , Wos, E. J. , Qin, R. , Mattar, B. I. , Green, N. B. ... - - Support Care Cancer - 2011 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N06CA
A randomized controlled trial evaluating a topical treatment for chemotherapy-induced neuropathy: NCCTG trial N06CA Barton, D. L. , Wos, E. , Qin, R. , Mattar, B. , Green, N. , Lanier, K. ... - - J. Clin. Oncol. - 2009 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N06CA
Adiponectin: A novel biomarker for cancer- related fatigue?; NCCTG study N07C2 (Alliance) Barton, D. , Liu, H. , Tan, A. , Sloan, J. ... - MASCC / ISOO - Support Care Cancer - 2013 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - N07C2
The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9 Barton, Debra L. , Burger, Kelli , Novotny, Paul J. , Fitch, Tom R. ... - - Support Care Cancer - 2013 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N00C9
Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance) Barton, Debra L. , Shuster, Lynne T. , Dockter, Travis ... - - Support Care Cancer - 2018 Manuscript - Secondary Endpoint - Primary Analysis - Symptom Inter - N10C1
Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance) Barton, Debra L. , Sloan, Jeff A. , Shuster, Lynne T. , Gill, Paula ... - - Support Care Cancer - 2018 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N10C1
Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance) Barton, Debra L. , Sloan, Jeff A. , Shuster, Lynne T , Gill, Paula ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N10C1
Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA Barton, Debra L. , Soori, Gamini S. , Bauer, Brent A. ... - - Support Care Cancer - 2010 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N03CA
Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy, NCCTG N08C3 (Alliance) Barton, Debra L. , Thanarajasingam, Gita , Sloan, Jeff A. ... - - Cancer - 2014 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N08C3
Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. Barton, Debra L , Wender, Donald B , Sloan, Jeff A , Dalton, Robert J ... - - J. Natl. Cancer Inst. - 2007 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - NCCTG-N02C3
Addressing the Complexities of Sexual Health in Female Cancer Survivors: NCCTG N10C1 (Alliance) Barton, Debra , Dockter, Travis , Atherton, Pamela , Lester, Joanne ... - CANS - - 2014 Abstract - Secondary Endpoint - Primary Analysis - Symptom Inter - N10C1
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials Basch, Ethan , Dueck, Amylou C. , Rogak, Lauren J. ... - - JAMA Oncol - 2017 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Health Outcome - CALGB-30607 , CALGB-30610 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-70501 , CALGB-70604 , CALGB-80405 , CALGB-90401
Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048 Basch, Ethan , Dueck, Amylou C. , Rogak, Lauren J. ... - - J. Clin. Oncol - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Health Outcome - N1048
Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-Institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002) Bashey, Asad , Owzar, Kouros , Johnson, Jeffrey L. ... - - Biol. Blood Marrow Transplant. - 2011 Manuscript - Primary Endpoint - Primary Analysis - Transplant - CALGB-100002
Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study Becker, H. , Maharry, K. , Radmacher, M. D. , Margeson, D. ... - - Blood - 2010 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML) Becker, H. , Marcucci, G. , Maharry, K. , Margeson, D. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10201 , CALGB-20202 , CALGB-8461 , CALGB-9720
Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (>= 60 years y ) and Younger (< 60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. D. ... - - Blood - 2009 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
CEBPA double mutations impact favorably on the outcome of older adults with wild-type NPM1 cytogenetically normal acute myeloid leukemia and are associated with distinct gene- and microRNA-expression patterns Becker, H. , Marcucci, G. , Maharry, K. , Radmacher, M. , Wu, Y. ... - - Haematologica - 2010 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9665 , CALGB-9720
Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8 Becker, Heiko , Maharry, Kati , Mrózek, Krzysztof , Volinia, Stefano ... - - Leukemia - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8923 , CALGB-9022 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study Becker, Heiko , Maharry, Kati , Radmacher, Michael D. ... - - Haematologica - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-20502 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study Becker, Heiko , Marcucci, Guido , Maharry, Kati ... - - Blood - 2010 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study Becker, Heiko , Marcucci, Guido , Maharry, Kati ... - - J Clin Oncol - 2010 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10201 , CALGB-19808 , CALGB-20202 , CALGB-8461 , CALGB-9720
Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy Beltran, Himisha , Wyatt, Alexander W , Chedgy, Edmund C ... - - Clin. Cancer Res. - 2017 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90203
Evaluation of mode equivalence of the MSKCC Bowel Function Instrument, LASA Quality of Life, and Subjective Significance Questionnaire items administered by Web, interactive voice response system (IVRS), and paper Bennett, Antonia V. , Keenoy, Kathleen , Shouery, Marwan ... - - Qual Life Res - 2016 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - NCT01458509
Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - ASCO - J Clin Oncol - 2019 Abstract - Primary Endpoint - Primary Analysis - GI - A021202
Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - NANETS - Pancreas - 2019 Abstract - Primary Endpoint - Primary Analysis - GI - A021202
Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trials Bernhard, Jürg , Luo, Weixiu , Ribi, Karin , Colleoni, Marco ... - - Lancet Oncol. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials Berry, D. A. , Ueno, N. T. , Johnson, M. M. , Lei, X. , Lopez, V. ... - - Breast Cancer Res. Treat. - 2007 Abstract - Primary Endpoint - Primary Analysis - Breast - INT-0163
High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials Berry, Donald A. , Ueno, Naoto T. , Johnson, Marcella M. ... - - J. Clin. Oncol - 2011 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Breast - INT-0163
Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581 Bertagnolli, M. M. , Niedzwiecki, D. , Hall, M. , Jewell, S. D. ... - ASCO - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - GI - C9581
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 Bertagnolli, Monica M. , Niedzwiecki, Donna , Compton, Carolyn C. ... - - J Clin Oncol - 2009 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-150705 , CALGB-89803
Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803 Bertagnolli, Monica M. , Redston, Mark , Compton, Carolyn C. ... - - J Clin Oncol - 2011 Manuscript - Primary Endpoint - Primary Analysis - GI - C150705 , C89803 , C9581
p27Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803 Bertagnolli, Monica M. , Warren, Robert S. , Niedzwiecki, Donna ... - - Clin Cancer Res - 2009 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-150705 , C89803
Effect of age on the pharmacokinetics of busulfan (Bu): An Alliance study. Beumer, J. H. , Lewis, L. D. , Owzar, K. , Jiang, C. , Holleran, J. L. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary Endpoint - Primary Analysis - PPP - CALGB-10503 , CALGB-19808 , CALGB-100103
Effect of Age on the Pharmacokinetics of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation; an Alliance study (CALGB 10503, 19808, and 100103) Beumer, Jan H. , Owzar, Kouros , Lewis, Lionel D. , Jiang, Chen ... - - Cancer Chemother. Pharmacol. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - PPP - C19808 , CALGB-100103 , CALGB-10503
Sequencing symptom control: Results from the Alliance N08C1 and N08CA genetics of chemotherapy neuropathy trials Beutler, A. S. , Kulkarni, A. , Kanwar, R. , Qin, R. ... - AACR - AACR 2013 Annual Meeting - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Symptom Inter - N08C1 , N08CA
Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy Beutler, Andreas S. , Kulkarni, Amit A. , Kanwar, Rahul ... - - Ann. Neurol. - 2014 Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Symptom Inter - N08C1 , N08CA
An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Bhardwaj, S , Holland, J F ... - - Cancer Invest. - 1993 Manuscript - Primary Endpoint - Primary Analysis - Breast - C8743
Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3) Bhatnagar, B , Blachly, JS , Kohlschmidt, J , Eisfeld, A-K ... - - Leukemia - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , CALGB-20202 , C8525 , CALGB-10102 , CALGB-10201 , CALGB-10503 , CALGB-10603 , CALGB-11002 , CALGB-19808 , CALGB-8923 , CALGB-9120 , CALGB-9222 , CALGB-9621 , CALGB-9720
Acute myeloid leukemia (AML) patients with an isolated trisomy display increased frequency of spliceosome mutations CALGB 8461 and 20202 (Alliance) Bhatnagar, Bhavana , Eisfeld, Ann-Kathrin , Mrózek, Krzysztof ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia Bhatnagar, Bhavana , Eisfeld, Ann-Kathrin , Nicolet, Deedra ... - - Br. J. Haematol. - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-9222 , CALGB-9621 , CALGB-9720
Discovery of SNPs associated with chemotherapy-induced peripheral neuropathy (CIPN) using model estimated parameters as phenotypes CALGB 40502 (Alliance) Bhongsatiern, Jiraganya , Carbonetto, P. , Chua, Katherina C. ... - ASCPT - CLINICAL PHARMACOLOGY & THERAPEUTICS - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40502
Mutational Landscape and Clinical Outcome Associated with Different Rearrangements Involving 11q23/MLL in De Novo Acute Myeloid Leukemia (AML) CALB 8461 and 20202 (Alliance) Bill, Marius , Eisfeld, Ann-Kathrin , Mrózek, Krzysztof ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461
Prognostic impact of the 2017 European Leukemianet (ELN) classification of adult patients (pts) with acute myeloid leukemia (AML) treated on Cancer and Leukemia Group B (CALGB)/Alliance protocols Bill, Marius , Mrózek, K , Kohlschmidt, J. , Nicolet, D. ... - EHA - HemaSphere - 2019 Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Leuk Corr Sci - C8461 , CALGB-20202 , CALGB-9665
A 17-gene leukemia stem cell (LSC) score in adult patients (pts) with acute myeloid leukemia (AML) reveals a distinct mutational landscape and refines current European Leukemianet (ELN) genetic risk stratification (Alliance) Bill, Marius , Nicolet, Deedra , Eisfeld, Ann-Kathrin ... - ASH - Blood - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20202 , CALGB-8461
Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. Bill, Marius , Nicolet, Deedra , Kohlschmidt, Jessica ... - - Haematologica - 2020 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8621 , CALGB-8461 , C8721 , CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-11001 , CALGB-11002 , CALGB-19808 , CALGB-20202 , CALGB-8525 , CALGB-8821 , CALGB-8923 , CALGB-9022 , CALGB-9120 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720
Prognostic and biologic significance of transfer RNA-derived small RNAs(tsRNAs) expression in younger adult patients (pts) with cytogenetically normal acute myeloid leukemia (CN-AML) Bill, Marius , Veneziano, Dario , Kohlschmidt, Jessica ... - ASH - Blood - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C8461 , C9665 , CALGB-20202
Perioperative Patient Reported Outcomes Predict Serious Postoperative Complications: A Secondary Analysis of the COST Trial Bingener, Juliane , Sloan, Jeff A. , Novotny, Paul J. ... - - J. Gastrointest. Surg. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Health Outcome - NCCTG-93-46-53
Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105 Blackstock, A. W. , Socinski, M. A. , Bogart, J. , Gu, L. , Wang, X. ... - - J. Clin. Oncol. - 2006 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30105
Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials Blanke, C. D. , Bot, B. M. , Thomas, D. M. , Bleyer, A. , Kohne, C. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-N9741
Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials Blanke, Charles D. , Bot, Brian M. , Thomas, David M. ... - - J. Clin. Oncol - 2011 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9741
Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. Bleiberg, H. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-79-41-51 , NCCTG-83-41-51
Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Bloch, Orin , Shi, Qian , Anderson, S. Keith , Knopp, Michael ... - SNO - Neuro-Oncology - 2017 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - A071101
Cognitive Function and Discontinuation of Adjuvant Hormonal Therapy in Older Breast Cancer Survivors: CALGB 369901 (Alliance) Bluethmann, Shirley M. , Alfano, Catherine M. , Clapp, Jonathan D. ... - - Breast Cancer Res. Treat. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-369901
Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502 Blum, K. A. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2008 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50502
Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism Blum, K. A. , Jung, S.-H. , Johnson, J. L. , Lin, T. S. , Hsi, E. D. ... - - Ann Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50502
Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance) Blum, Kristie A. , Jung, Sin-Ho , Barak, Ian , Hsi, Eric D. ... - ASH - Blood - 2017 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50904
Randomized Trial of Ofatumumab and Bendamustine versus Ofatumumab, Bendamustine and Bortezomib in previously untreated patients with highrisk follicular lymphoma: CALGB 50904 (Alliance) Blum, Kristie A. , Polley, Mei-Yin , Jung, Sin-Ho ... - - Cancer - 2019 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50904
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Blum, Kristie A , Johnson, Jeffrey L , Niedzwiecki, Donna ... - - Leuk. Lymphoma - 2007 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50206
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Blum, Kristie A , Johnson, Jeffrey L , Niedzwiecki, Donna ... - - Cancer -
